Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival

Pathology and Oncology Research

Volumn 17, Issue 3, 2011, Pages 511-518

  Halon, Agnieszka ^a   Materna, Verena ^b   Drag Zalesinska, Malgorzata ^a   Nowak Markwitz, Ewa ^c   Gansukh, Tserenchunt ^d   Donizy, Piotr ^a   Spaczynski, Marek ^c   Zabel, MacIej ^a,c   Dietel, Manfred ^b   Lage, Hermann ^b   Surowiak, Pawel ^a,b,e  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^e Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

Author keywords

Cisplatin; Estrogen receptor alpha; Immunohistochemistry; Ovarian cancer

Indexed keywords

CISPLATIN; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG SENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAPAROTOMY; MALIGNANT TRANSFORMATION; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL TIME; TISSUE DISTRIBUTION;

CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 80052713086     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-010-9340-0     Document Type: Article

References (29)

1. G Lazannec 2006 Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis Cancer Lett 231 151 157 10.1016/j.canlet. 2005.01.021 (Pubitemid 43038725)
2. ST Pearce VC Jordan 2004 The biological role of estrogen receptors α and β in cancer Crit Rev Oncol Hematol 50 3 22 15094156 10.1016/j.critrevonc.2003.09.003 (Pubitemid 38501614)
3. PR Lindgren S Cajander T Bäckström, et al. 2004 Estrogen and progesterone receptors in ovarian epithelial tumors Mol Cell Endocrinol 221 97 104 15223136 10.1016/j.mce.2004.02.020 1:CAS:528:DC%2BD2cXlt1Wgsrs%3D (Pubitemid 38829727)
4. P Pujol JM Rey P Nirde, et al. 1998 Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis Cancer Res 58 5367 5373 9850067 1:CAS:528:DyaK1cXotVSktLs%3D (Pubitemid 28551118)
5. T Rutheford WD Brown E Sapi, et al. 2000 Absence of estrogen receptor-beta expression in metastatic ovarian cancer Obstet Gynecol 96 417 421 10.1016/S0029-7844(00)00917-0
6. S Cunat P Hoffmann P Pujol 2004 Estrogens and epithelial ovarian cancer Gynecol Oncol 94 25 32 15262115 10.1016/j.ygyno.2004.03.026 1:CAS:528: DC%2BD2cXlslOqsLk%3D (Pubitemid 38950494)
7. SG Hiller RA Anderson AR Williams, et al. 1998 Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells Mol Hum Reprod 4 811 815 10.1093/molehr/4.8.811 (Pubitemid 28392026)
8. AW Brandenberger MK Tee RB Jaffe 1998 Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues J Clin Endocrinol Metab 83 1025 1028 9506768 10.1210/jc.83.3.1025 1:CAS:528:DyaK1cXivFOgsbc%3D (Pubitemid 28496985)
9. J Kurebayashi 2003 Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance Breast Cancer 10 112 119 12736563 10.1007/BF02967635
10. M Harries SB Kaye 2001 Recent advances in the treatment of epithelial ovarian cancer Expert Opin Investig Drugs 10 1715 1724 11772280 10.1517/13543784.10.9.1715 1:CAS:528:DC%2BD3MXms1Sntr0%3D (Pubitemid 32827430)
11. EF McClay KD Albright JA Jones, et al. 1994 Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines Br J Cancer 70 449 452 8080729 10.1038/bjc.1994.326 1:CAS:528: DyaK2cXmsVGnsb0%3D (Pubitemid 24268546)
12. V Materna B Liedert J Homale, et al. 2005 Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells Int J Cancer 115 393 402 15688364 10.1002/ijc.20899 1:CAS:528:DC%2BD2MXkt1Clurw%3D (Pubitemid 40663743)
13. V Materna A Stege P Surowiak, et al. 2006 RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells Biochem Biophys Res Commun 348 153 157 16876126 10.1016/j.bbrc.2006.07.022 1:CAS:528:DC%2BD28Xot1Wqtbo%3D (Pubitemid 44163494)
14. P Kowalski P Surowiak H Lage 2005 Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP Mol Ther 11 508 522 15771954 10.1016/j.ymthe.2004.11.016 1:CAS:528:DC%2BD2MXisVClsb0%3D (Pubitemid 40353109)
15. P Surowiak V Materna I Kaplenko, et al. 2006 ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome Clin Cancer Res 12 7149 7158 17145840 10.1158/1078-0432.CCR-06-0564 1:CAS:528:DC%2BD28Xht1Kns7bI (Pubitemid 44974516)
16. B Györffy P Surowiak O Kiesslich, et al. 2006 Resistance prediction profile for eleven anticancer agents at clinical concentrations based on the gene expression pattern of thirty cell lines Int J Cancer 118 1699 1712 16217747 10.1002/ijc.21570 (Pubitemid 43376433)
17. Sobin LH, Wittekind Ch (eds) (1997) UICC TNM Classification of malignant tumors. Wiley-Liss, New York
18. Y Shimizu S Kamoi S Amada, et al. 1998 Toward the development of a universal grading system of ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up Cancer 82 893 901 9486579 10.1002/(SICI)1097-0142(19980301)82:5<893::AID- CNCR14>3.0.CO;2-W 1:STN:280:DyaK1c7ksF2rtg%3D%3D (Pubitemid 28104169)
19. W Remmele HE Stenger 1987 Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe 8 138 140 3303008 1:STN:280:DyaL2s3ovFGhsQ%3D%3D
20. PL Fitzgibbons DL Page D Weaver, et al. 2000 Prognostic factors in breast cancer. college of american pathologists consensus statement 1999 Arch Pathol Lab Med 124 966 978 10888772 1:STN:280:DC%2BD3czptVKrtQ%3D%3D
21. Y Ogawa T Moriya Y Kato, et al. 2004 Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy Breast Cancer 11 267 275 15550845 10.1007/BF02984548
22. A Burges A Brüning C Dannenmann, et al. 2010 Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary Arch Gynecol Obstet 281 511 517 19639330 10.1007/s00404-009-1185-y 1:CAS:528:DC%2BC3cXhtlekt74%3D
23. P Lee DG Rosen C Zhu, et al. 2005 Expression of progesterone receptor is favorable prognostic marker in ovarian cancer Gynecol Oncol 96 671 677 15721410 10.1016/j.ygyno.2004.11.010 1:CAS:528:DC%2BD2MXhsVOjsrs%3D (Pubitemid 40255486)
24. AJ Li RL Baldwin BY Karlan 2003 Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures Am J Obstet Gynecol 189 22 27 12861133 10.1067/mob.2003.328 1:CAS:528: DC%2BD3sXls1ersLs%3D (Pubitemid 36886519)
25. JL Hecht J Kotsopoulos SE Hankinson, et al. 2009 Relationship between epidemiological risk and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study Cancer Epidemiol Biomark Prev 18 1 14 10.1158/1055-9965.EPI-08-1214 1:CAS:528:DC%2BD1MXosFyitQ%3D%3D
26. H Sakaguchi J Fujimoto I Aoki, et al. 2002 Expression of oestrogen receptor a and b in uterine endometrial and ovarian cancers Eur J Cancer 38 S74 S75 12409085 10.1016/S0959-8049(02)00296-4
27. KC Chao PH Wang MS Yen, et al. 2005 Role of estrogen and progesterone in the survival of ovarian tumors-a study of the human ovarian adenocarcinoma cell line OC-117-VGH J Chin Med Assoc 68 360 367 16138714 10.1016/S1726-4901(09) 70176-5 1:CAS:528:DC%2BD2MXhtVClu7jP
28. SH Park LW Cheung AS Wong, et al. 2008 Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor α Mol Endocrinol 22 2085 2098 18550773 10.1210/me.2007-0512 1:CAS:528:DC%2BD1cXhtV2itL%2FP
29. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D